Upadacitinib

(Rinvoq®)

Rinvoq®

Drug updated on 11/14/2023

Dosage FormExtended-release tablet (oral: 15 mg, 30 mg, 45 mg)
Drug ClassJanus kinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
  • For the treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blocker.
  • For the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
  • For the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blocker.
  • For the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers.
  • For the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Rinvoq (upadacitinib) Prescribing Information.2022AbbVie Inc., North Chicago, IL

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Australian public assessment report for Rinvoq.2023EMA
Upadacitinib for treating moderately to severely active ulcerative colitis.2023NICE
Upadacitinib for treating active non-radiographic axial spondyloarthritis.2023NICE
Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.2023Heliyon
Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis.2023BMJ Journals
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs.2022NICE
Systemic immunomodulatory treatments for atopic dermatitis update of a living systematic review and network meta-analysis. 2022JAMA Dermatology
Association between Janus kinase inhibitors therapy and mental health outcome in rheumatoid arthritis: a systematic review and meta-analysis. 2022Rheumatology and Therapy
Clinical and pharmacoeconomic combined report: upadacitinib (Rinvoq) –Atopic Dermatitis.2022CADTH
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis.2022NICE
The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta analysis.2022European Journal of Clinical Pharmacology
Upadacitinib for treating active ankylosing spondylitis. 2022NICE
Long-term effectiveness and safety of biologic and small molecule drugs for moderate to severe atopic dermatitis: a systematic review.2022Life
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis.2022Rheumatology
Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis. 2022Dermatologic Therapy
Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: systematic review and network meta-analysis.2022Dermatology and Therapy
Comparative efficacy and safety of Janus kinase inhibitors and secukinumab in patients with active ankylosing spondylitis: a systematic review and meta-analysis.2022Pharmacology
Are janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis.2022International Journal of Rheumatic Diseases
Clinical and pharmacoeconomic combined report: upadacitinib (Rinvoq) - Psoriatic arthritis. 2021CADTH
JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value.2021ICER
Upadacitinib for treating moderate rheumatoid arthritis. 2021NICE
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. 2021Journal of the European Academy of Dermatology and Venereology
Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis.2021European Journal of Allergy and Clinical Immunology
Short-term effectiveness and safety of biologics and small molecule drugs for moderate to severe atopic dermatitis: a systematic review and network meta-analysis. 2021Life
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis.2021Therapeutic Advances in Musculoskeletal Disease
Systematic review on the efficacy and safety of oral Janus kinase inhibitors for the treatment of atopic dermatitis. 2021Frontiers in Medicine
The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: a systematic review and network meta-analysis. 2021Dermatologic Therapy
Efficacy and safety of Janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis. 2021Dermatology
Upadacitinib for treating severe rheumatoid arthritis.2020NICE
Comparative efficacy and safety of 15 and 30 mg upadacitinib administered to patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. 2020Zeitschrift für Rheumatologie
Clinical review report: upadacitinib (Rinvoq) - Rheumatoid arthritis.2020CADTH
Janus kinase inhibitors and biosimilars for rheumatoid arthritis: effectiveness and value. 2020ICER
Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. 2020Mayo Clinic
Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. 2019Immunotherapy
Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. 2019International Journal of Rheumatic Diseases
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. 2019Rheumatology (Oxford)
Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. 2018Annals of Rheumatic Diseases

Clinical Practice Guidelines